PROTEINTECH-GROUP
20.3.2024 19:58:26 CET | Business Wire | Press release
Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320643097/en/
Proteintech celebrates the opening with a ribbon cutting event. Pictured: Dr. Jason Li, CEO of Proteintech, along with Proteintech executives and local government officials. (Photo: Business Wire)
In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-based reagents and was located at the incubator IZB. The gradual integration of Chromotek into the parent company, Proteintech Group, enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the European Union.
Rainer Gebhart, Site Manager at Proteintech Germany, said: “Here we offer state-of-the-art working environments for daily top performance and innovation of our employees - our most important capital for a continued successful future.” He also explained, “The move supports our customer focused strategy. With a larger team in Martinsried – and in cooperation with our sister site in Manchester, UK – we can better serve our customers in Europe and further gain market share.”
Dr Jason Li, CEO of Proteintech said, “There is a great future for Nanobody technology and we’re excited to be at the forefront of this.” He also stated, “Proteintech has R&D and production laboratories on three continents in its major sites (Chicago, Wuhan and Martinsried). All three sites have seen expansion in the past year and the collaboration between them means we can bring new and innovative products to the market.”
About Proteintech Group
Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 200,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.
To learn more about Proteintech, please visit www.ptglab.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320643097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 16:00:00 CET | Press release
Short film follows consumers across three countries whose stories demonstrate the power of financial inclusion, innovation and resilienceKey highlights: New Experian documentary features five individuals from the United States, Brazil and the United Kingdom whose experiences illustrate the impact of financial access and opportunity. Documentary highlights examples spanning debt relief, financial education, credit empowerment and healthcare innovation. Stories showcase how Experian's products, services and social innovation can help consumers navigate challenges and pursue personal and financial goals. For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passi
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 15:32:00 CET | Press release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 15:00:00 CET | Press release
FSA/HSA-Eligible Recovery Boots Deliver Five Levels of Heat and Seven Levels of Compression, Available for Pre-Order Now Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation h
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 15:00:00 CET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
European Commission expands license for Alfasigma’s Jyseleca® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 15:00:00 CET | Press release
Jyseleca® (filgotinib) has received expanded approval for the treatment of patients with active axial spondylarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have not responded adequately to conventional therapy. EC approval follows a positive opinion from the CHMP in September 2026 and offers a new treatment option for people living with inadequately controlled axSpA in Europe. An application has been submitted to the MHRA for UK approval and is under review. In the OLINGUITO Phase 3 study, improvements in the signs and symptoms of axSpA – including spinal pain – were observed early and maintained over 52 weeks of treatment with filgotinib. This new indication builds on previous approvals for Jyseleca® for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis in Europe and the United Kingdom. The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom